News

RSS

CABG vs. PCI for Multivessel CAD: Do Second-Generation Stents Make a Difference (17 Mar 2015)

Second-generation stents narrow the gap between coronary artery bypass grafting and percutaneous coronary intervention for nondiabetic patients with multivessel disease.

Vitamin D Supplements Do Not Appear to Lower Blood Pressure (17 Mar 2015)

Vitamin D supplements do not effectively lower blood pressure, according to a systematic review and meta-analysis in JAMA Internal Medicine. Low serum vitamin D levels have previously been associated with elevated blood pressure and cardiovascular events.

ACP Recommends Against Screening Asymptomatic Adults for Cardiac Disease (17 Mar 2015)

The American College of Physicians has recommended that clinicians should not screen low-risk, asymptomatic adults for heart disease.

Folic Acid Supplementation Helps Reduce Stroke Risk in Certain Populations (16 Mar 2015)

Supplementation with folic acid might help prevent stroke in adults with hypertension — particularly in those with low serum folate levels — according to a study presented on Sunday at the American College of Cardiology conference in San Diego and published in JAMA. Over 20,000 Chinese adults with hypertension and without histories of MI or…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

A Requiem for Routine Thrombectomy? (16 Mar 2015)

Primary PCI is the treatment of choice in the early period of an acute MI. One limitation is the risk of dislodging part of the clot, leading to new downstream blockages of the microvasculature. One strategy that has been under development for a long time is thrombectomy, in which a device extracts the clot prior…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Encouraging 5-Year Results for TAVR (15 Mar 2015)

The publication five years ago of the two-part PARTNER trial brought a major change to the treatment of aortic valve replacement. The trial demonstrated that transcatheter aortic valve replacement (TAVR) was a reasonable treatment option, first for patients who were not surgical candidates and then for patients who were at high risk for surgery. One…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

More Information Emerges About the PCSK9 Inhibitors (15 Mar 2015)

New information emerged today about two new cholesterol-lowering drugs that have been attracting a lot of attention. Data about the PCSK9 inhibitors — evolocumab, under development by Amgen, and alirocumab, under development by Sanofi and Regeneron — were presented at the American College of Cardiology meeting in San Diego and published simultaneously in the New England Journal of…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Has CT Angiography Lived Up to Its Early Promise? (14 Mar 2015)

Computed tomographic angiography (CTA) enjoyed an explosion of growth over the past decade or more, fueled by enthusiasm for its ability to deliver speedy, high-resolution images of the coronary arteries. Many anticipated that CTA would prove its worth and justify its expense and radiation dose. As explained by one cardiologist, Duke University’s Dan Mark, with…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

DAPT ‘Approaching the Point of Diminishing Returns’? (14 Mar 2015)

After a myocardial infarction (MI), patients remain at high risk for recurrent events. The precise role of dual antiplatelet therapy (DAPT) to lower this risk has been the subject of considerable disagreement.  Now a new study offers fresh evidence that prolonged DAPT can lower risk over a long period, but only at the cost of…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

FDA Approves Watchman Left Atrial Appendage Closure Device for AF (14 Mar 2015)

The FDA has approved Boston Scientific’s long-delayed Watchman Left Atrial Appendage Closure Device. According to the company, the Watchman is indicated as an alternative to long-term warfarin therapy for the reduction of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation at increased risk for stroke and systemic embolism. Although an alternative to…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.